Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
We present the fourth case of an adult man (29 yr old) affected by aromatase deficiency resulting from a novel homozygous inactivating mutation of the CYP19 (P450(arom)) gene. At first observation, continuing linear growth, eunuchoid body proportions, diffuse bone pain, and bilateral cryptorchidism were observed. The patient presented also a complex dysmetabolic syndrome characterized by insulin resistance, diabetes mellitus type 2, acanthosis nigricans, liver steatohepatitis, and signs of precocious atherogenesis. The analysis of the effects induced by the successive treatment with high doses of testosterone, alendronate, and estradiol allows further insight into the roles of androgens and estrogens on several metabolic functions. High doses of testosterone treatment resulted in a severe imbalance in the estradiol to testosterone ratio together with the occurrence of insulin resistance and diabetes mellitus type 2. Estrogen treatment resulted in an improvement of acanthosis nigricans, insulin resistance, and liver steatohepatitis, coupled with a better glycemic control and the disappearance of two carotid plaques. Furthermore, the study confirms previous data concerning the key role of estrogens on male bone maturation, at least in part, and regulation of gonadotropin secretion. The biopsy of the testis showed a pattern of total germ cell depletion that might be due to the concomitant presence of bilateral cryptorchidism. Thus, a possible role of estrogen in male reproductive function is suggested but without revealing a direct cause-effect relationship. Data from this case provide new insights into the role of estrogens in glucose, lipid, and liver metabolism in men. This new case of aromatase deficiency confirms previous data on bone maturation and mineralization, and it reveals a high risk for the precocious development of cardiovascular disease in young aromatase-deficient men.
Maffei
Laura
L
Consultorios Asociados de Endocrinologia, 1425 Buenos Aires, Argentina.
Murata
Yoko
Y
Rochira
Vincenzo
V
Tubert
Gloria
G
Aranda
Claudio
C
Vazquez
Marcela
M
Clyne
Colin D
CD
Davis
Susan
S
Simpson
Evan R
ER
Carani
Cesare
C
D000052:Acanthosis Nigricans / Q000188:drug therapy / Q000235:genetics; D000328:Adult; D019386:Alendronate / Q000008:administration & dosage*; D001141:Aromatase / Q000172:deficiency* / Q000235:genetics*; D001161:Arteriosclerosis / Q000235:genetics; D001842:Bone and Bones; D003456:Cryptorchidism / Q000235:genetics / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D005234:Fatty Liver / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008099:Liver / Q000378:metabolism / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009154:Mutation; D010146:Pain; D013577:Syndrome; D013737:Testis / Q000473:pathology; D013739:Testosterone / Q000008:administration & dosage* / Q000097:blood
D008055:Lipids; D013739:Testosterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D001141:Aromatase; D019386:Alendronate